Navigation Links
5th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded
Date:3/16/2010

warded annually to a scientist, nominated by colleagues or peers, who has contributed outstanding, substantial research to the fight against cancer and whose accomplishments have helped improve treatment options for cancer patients. The Prize includes a $25,000 cash award and will be presented to Dr. Vogt on March 16, 2010 at the Hilton New York at an award ceremony featuring a keynote address by John Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer, Eli Lilly and Company.

"I am immensely grateful and delighted to be awarded the 2010 Albert Szent-Gyrgyi Prize for Progress in Cancer Research," said Dr. Vogt. "This award marks a milestone in my scientific career and gives me both encouragement and inspiration. Albert Szent-Gyrgyi's consuming interest during the last two decades of his life was cancer. Being a fiercely independent man, he chose an unusual path to support his research: the establishment of a private foundation. By the power of his personality and his scientific stature, he succeeded in creating the National Foundation for Cancer Research. For almost 40 years, the unique focus of NFCR on research has provided critical support to innovative scientists and has advanced the translation of basic knowledge into successful therapy."

Dr. Peter Vogt's revolutionary research on src has led to the discovery of additional oncogenes, including myc, jun, and PI 3-kinase, that play a key role in human cancer and have become household names in the world of cellular signaling research. His current work on cancer-specific mutations in p110, the catalytic subunit of PI 3-kinase, has demonstrated that these mutations confer oncogenic activity on the protein, making them highly specific cancer targets. Pursuing these targets, Dr. Vogt is now generating small molecule inhibitors that can interfere with their role in cancer causation. Dr. Vogt's iconic career may have begun with oncogene discovery but it has expanded in scope and now in
'/>"/>

Contact: Silas Deane
sdeane@nfcr.org
615-319-6007
National Foundation for Cancer Research
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. University of Chicago and Ataxia Foundation team up for annual scientific and patient meetings
2. P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting
3. Society of Interventional Radiology hosts 35th Annual Scientific Meeting
4. Press registration open for Society of Interventional Radiology’s 35th Annual Scientific Meeting
5. SCM Microsystems Announces Results of Annual Meeting
6. 2009 Annual Meetings emphasize sustainability
7. TGen provides Arizona with $77 million in annual economic impact
8. Quality of medicines and food ingredients the focus at USP 2009 Annual Scientific Meeting
9. Annual survey shows high numbers of seed scallops on Georges Bank, low numbers in Mid-Atlantic
10. Science communication to take the stage at annual AAAS meeting in San Francisco
11. Symposium to discuss geoengineering to fight climate change at the ESA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... A class of Alzheimer,s disease drugs currently studied ... traumatic brain injury in animals, researchers at Georgetown University ... of Nature Medicine . They say the ... do something no other drug has been able to ...
... a common feature of prion disease-affected human, mouse, and ... Neena Singh and colleagues at Case Western Reserve University ... findings, published March 13 in the open-access journal ... of neurotoxicity in prion disorders, and novel avenues for ...
... consumption are undisputable, although some data suggest that ... For instance, several studies have reported a positive ... (BMD) in older women. There are fewer studies ... and none have considered different classes of alcoholic ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Iron is involved in prion disease-associated neuronal demise 2
(Date:5/1/2015)... TRIANGLE PARK, N.C. , May 1, 2015  United ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer of ... company,s business at the Deutsche Bank 40 th Annual ... The presentation will take place on Wednesday, May ... accessed via a live webcast on the United Therapeutics website ...
(Date:4/30/2015)... --  Tamir Biotechnology , a leading developer of RNA ... antiviral therapy program. Clinical Progress ... evaluated and considered by a number of clinicians on ... first quarter of 2015, the company participated in the ... of Potential Treatments and Vaccines For Ebola In West ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Nitto ... today announces its increased capacity and production capability ... increased client variety and service fulfillment continues to ... improve process throughput capacities. , ... newly installed downstream process equipment at its Milford, ...
(Date:4/30/2015)... Hungary (PRWEB) April 30, 2015 ... lab notebook with integrated protocols and specimen management ... software solutions and consulting services for life science ... development of Labguru’s newest feature: chemical structure and ... domain features for biologists, bio-chemists, and more, the ...
Breaking Biology Technology:Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... Sept. 18 Caliper Life,Sciences, Inc. (Nasdaq: ... the,UBS Global Life Sciences Conference in New York ... at 3:30 p.m. EDT. Kevin Hrusovsky, President,and CEO ... the company,s business.,The audio-only webcast can be accessed ...
... /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a biotechnology ... therapeutics, today announced that ARIUS Research Inc.,shareholders and ... the Company and Roche., At a special ... ARIUS,shareholders and warrant holders approved the transaction, with ...
... MADISON, Wis., Sept. 18 Cellectar, Inc., a,privately-held ... treat and monitor human cancers, today announced the,appointment ... Board of,Directors., Mr. Harwood, 55, is a ... private equity firm. Prior to working with Avista,Mr. ...
Cached Biology Technology:ARIUS sale approved by shareholders 2Charles C. Harwood, Jr., Joins Cellectar, Inc.'s Board of Directors 2
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Selenoprotein P Purified Anti-Mouse clone 35, Isotype Mouse IgG 2b , 50 µg Consult technical datasheet for details....
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Biology Products: